A large proportion of melanomas harbour the activating BRAF V600E mutation that renders these cells dependent on MAPK signalling for their survival. Although the highly specific and clinically approved BRAF V600E kinase inhibitor, PLX4032, induces apoptosis of melanoma cells bearing this mutation, the underlying molecular mechanisms are not fully understood. Here, we reveal that PLX4032-induced apoptosis depends on the induction of the pro-apoptotic BH3-only protein PUMA with a minor contribution of its relative BIM. Apoptosis could be significantly augmented when PLX4032 was combined with an inhibitor of the pro-survival protein BCL-XL, whereas neutralization of the pro-survival family member BCL-2 caused no additional cell death. Although the initial response to PLX4032 in melanoma patients is very potent, resistance to the drug eventually develops and relapse occurs. Several factors can cause melanoma cells to develop resistance to PLX4032; one of them is the activation of the receptor tyrosine kinase cMET on melanoma cells by its ligand, hepatocyte growth factor (HGF), provided by the tumour microenvironment or the cancer cells themselves. We found that HGF mediates resistance of cMET-expressing BRAF mutant melanoma cells to PLX4032-induced apoptosis through downregulation of PUMA and BIM rather than by increasing the expression of pro-survival BCL-2-like proteins. These results suggest that resistance to PLX4032 may be overcome by specifically increasing the levels of PUMA and BIM in melanoma cells through alternative signalling cascades or by blocking pro-survival BCL-2 family members with suitable BH3 mimetic compounds.
mutation, which accounts for 70-90% of BRAF mutations that are found in melanomas. This T1799A transversion results in ã 500-fold increase in BRAF kinase activity, thereby driving MAPK signalling independent of external stimuli.
1,2 Activation of the MAPK pathway promotes proliferation and survival of cells through ERK1/2-mediated control of downstream target genes, including the negative regulation of the pro-apoptotic BCL-2 family member BIM. 3, 4 PLX4032 (Vemurafenib) is a clinically approved inhibitor specific for BRAF V600E . It causes cell cycle arrest and apoptosis in BRAF mutant melanomas but not in those expressing wild-type BRAF. 5 Previous studies demonstrated that apoptosis of BRAF V600E melanoma cells triggered by MEK1/2 inhibitors or PLX4032 was partially dependent on BIM, as RNA interference mediated knockdown of BIM significantly reduced cell killing, although it did not abolish it. 6, 7 This suggests that other pro-apoptotic BH3-only members of the BCL-2 family are likely to co-operate with BIM in PLX4032-induced apoptosis of these melanomas.
The BCL-2 protein family can be subdivided into three groups: the pro-survival proteins (BCL-2, BCL-XL, MCL-1, BFL-1/A1 and BCL-W), the BH3-only proteins (BIM, PUMA, NOXA, BID, BAD, HRK, BMF, BAD and BIK) and the multi-BH domain containing pro-apoptotic proteins, BAX, BAK and possibly BOK, which cause mitochondrial outer membrane permeabilization and thereby unleash cellular demolition by the caspases. 8, 9 The BH3-only proteins initiate apoptosis signalling either through direct activation of BAX/BAK or indirectly by binding to the pro-survival BCL-2-like proteins, thereby releasing BAX/BAK from their restraint by their pro-survival relatives. 10 Hence, inhibition of pro-survival BCL-2 family members by small molecule BH3 mimetics can initiate apoptosis signalling. ABT-737 is a BH3 mimetic that binds with high affinity to BCL-2, BCL-XL and BCL-W, but not to MCL-1 or BFL-1. 11 In cancers that are driven by aberrant expression of oncogenic kinases, potent synergy between ABT-737 and inhibitors of these kinases was observed. 12, 13 Although it has been reported that ABT-737 synergizes with PLX4032 or a MEK inhibitor in the killing of BRAF mutant melanoma cells, 6, 7, 14 for designing optimal combination therapies, it is crucial to understand which of the pro-survival family members targeted by this BH3 mimetic compound is essential for the sustained growth of melanoma cells. One feature melanocytes must acquire during their transformation to malignant melanoma is growth autonomy. Cell proliferation is normally dependent on growth factor receptormediated signalling. Not surprisingly, many cancers express high levels of growth factor receptors and sometimes even their ligands. Alternatively, the ligands can be provided by surrounding stromal cells. Accordingly, it was recently suggested that autonomous growth factor receptor-mediated signalling renders melanoma cells resistant to PLX4032 and therefore causes patients to relapse. 15 Specifically, it was reported that secretion of hepatocyte growth factor (HGF) from the tumour microenvironment and consequent activation of its receptor tyrosine kinase, cMET, which is expressed on a subset of the melanoma cells, promotes outgrowth of PLX4032-resistant cancer cells. 16, 17 In this study, we examined the importance of the intrinsic apoptotic pathway in PLX4032-induced killing of melanoma cells and its role in HGF/cMET signalling-driven resistance to this drug. Understanding these mechanisms will be crucial for the identification of novel therapeutic targets in BRAF V600E melanomas and possibly other cancers that express cMET.
Results
Human melanoma cells with the BRAF V600E mutation are killed by PLX4032. PLX4032 is a small molecule compound designed to inhibit the mutant BRAF V600E kinase, which drives activation of downstream kinases in the MAPK pathway, such as ERK1/2, thereby promoting proliferation and survival of melanoma cells. To investigate the molecular events by which PLX4032 mediates melanoma cell killing, we assembled a panel of well-characterized human melanoma cell lines and treated them with titrated doses of PLX4032 to determine their sensitivity to this agent. We found that PLX4032 induced significant dose-dependent apoptosis over a time course of 5 days in all BRAF mutant melanoma cell lines (M14, UACC257, Malme3M, SKMEL5 and UACC62), whereas the BRAF WT cells (CHL-1) were unaffected ( Figure 1a and Supplementary Figure 1a) . As expected and previously reported, 5 treatment with PLX4032 reduced phosphorylation of ERK1/2 in the BRAF V600E mutant melanoma cell lines, whereas ERK phosphorylation was paradoxically increased in the BRAF WT cell line (Figure 1b ). The sensitivity of the different melanoma cell lines to PLX4032-induced apoptosis was mirrored by the extent of repression of ERK1/2 activity, as reflected by reduction of ERK1/2 phosphorylation.
PUMA and to a lesser extent BIM are critical for PLX4032-induced apoptosis of BRAF V600E mutant melanoma cells. The pro-apoptotic BH3-only protein BIM has a crucial role in PLX4032-induced killing. 6 However, knockdown of BIM was not sufficient to completely abrogate PLX4032-induced cell death, 7, 14 which suggests that other pro-apoptotic BCL-2 family members may also contribute. To this end, we investigated changes in the expression of BH3-only proteins in melanoma cells upon treatment with PLX4032.
As expected, we observed strong upregulation of BIM in all BRAF mutant cells after 24 h of treatment ( Figure 2a and Supplementary Figure 1b) . Interestingly, we additionally observed significant increase in PUMA protein levels in all BRAF mutant cells but not in the BRAF wild-type (WT) melanoma cell line (Figure 2a and Supplementary  Figure 1b) . No consistent changes in BMF and NOXA levels were observed. Although PUMA has been reported as a transcriptional target of the tumour-suppressor p53, 18 ) and CHL-1 (BRAF WT ) were treated with DMSO (vehicle; -) or PLX4032 (+; at 3 μM) in the presence of the pan-caspase inhibitor Q-VD-OPh for 24 h before western blot analysis to detect pERK and total ERK protein levels. Probing for HSP70 was used as a loading control PLX4032-induced upregulation of PUMA (and also BIM) was independent of p53 ( Supplementary Figures 2a-c) .
To determine the functional relevance of PUMA upregulation in PLX4032-mediated killing of BRAF mutant melanoma cells, we generated BIM and PUMA single (M14, UACC62 and UACC257) and double knockout cell lines (M14 and UACC62), using CRISPR/Cas9. BIM and PUMA were each targeted with two independent sgRNAs against exon 2 or exon 3 of the genes: BIMEx2h, BIMEx3h, PUMAEx2h or PUMAEx3h. Efficient targeting of BIM and/or PUMA with the sgRNAs was already validated previously. 20, 21 Knockout of BIM and PUMA in both, single and double knockout cell lines, was verified, with these proteins being either undetectable or at least markedly reduced in all cell lines after treatment with PLX4032 ( Figure 2b and Supplementary Figure 1b) . As expected, PLX4032-induced upregulation of BIM and PUMA occurred normally in the control sgRNA transduced cell lines. Notably, the CRISPR/Cas9 knockout of BIM and PUMA was performed on a bulk cell population, rather than on single-cell clones, which excludes selection for potential unrelated mutations that could affect the response to PLX4032 during the single-cell cloning process. Importantly, PLX4032 treatment was still able to downregulate ERK activity in BIM and/or PUMA-deficient M14 and UACC257 cells, as reflected by the reduction in the levels of phosphorylated ERK (pERK) (Supplementary Figures 1b and c) . Owing to the relatively minor impact of PLX4032 on the UACC62 cells, we were unable to see any marked changes in pERK in these cells (Supplementary Figure 1b) . However, as BIM or PUMA were still upregulated in response to PLX4032 in the PUMA-or BIMdeficient variants, respectively, we are confident that the cellular pathways induced by mutant BRAF inhibition must be largely intact in these cells.
To examine the relative importance of PUMA and BIM in PLX4032-induced apoptosis in BRAF mutant melanomas, the single and double knockout cell lines were treated with PLX4032 and the extent of cell killing determined. Consistent with previous studies, 7, 14 we found that targeting BIM significantly reduced PLX4032-induced apoptosis, albeit to a relatively minor extent (Figure 2c and Supplementary  Figure 1d) . Interestingly, PUMA deficiency resulted in a more prominent protection from PLX4032-induced cell death and cell Primary human BRAF mutant melanoma cells upregulate PUMA and BIM upon treatment with PLX4032. In order to test the apoptotic response of low passage patient-derived melanoma cell lines, 22 we treated the BRAF V600E lines LM-MEL-28 and LM-MEL-33 and, as a control, the BRAF WT line, LM-MEL-34, with PLX4032. As expected, we observed significant killing of the two lines bearing mutant BRAF, whereas the BRAF WT cells were not adversely affected (Supplementary Figure 3) . Although no upregulation of proapoptotic BH3-only proteins was observed in the BRAF WT LM-MEL-34 cells, BIM was markedly upregulated in both BRAF V600E melanoma lines. However, PUMA was only upregulated in LM-MEL-28, but not in LM-MEL-33 cells (Figure 3a) . Interestingly, the LM-MEL-28 cells, were more efficiently killed by PLX4032 compared with the LM-MEL33 cells (Supplementary Figure 3) . This agrees with our previous observation that PUMA is the main killer protein in PLX4032-treated mutant BRAF melanoma cells, as strong upregulation of BIM was seen in both LM-MEL-28 and LM-MEL-33 cells (Figure 3a) , whereas only the LM-MEL-28 cells also showed marked upregulation of PUMA. Notably, when BIM S was overexpressed using a doxycycline-inducible lentiviral vector system, 23 LM-MEL-28 and LM-MEL-33 were killed with similar efficiencies. Enforced expression of the inert BIM S 4E mutant (negative control), 24 which does not bind to any pro-survival BCL-2 family members or BAX/BAK, had no impact ( Figure 3b ). This confirms that all of these cell lines contain the functional machinery, capable of activating the intrinsic apoptotic pathway. Collectively, these findings demonstrate that the pro-apoptotic BH3-only proteins PUMA and BIM are essential for PLX4032-induced killing of early passage BRAF V600E expressing patient-derived melanoma cells, similar to that observed in established cell lines (Figure 2 ).
BCL-XL inhibition significantly increases PLX4032-induced killing of BRAF mutant melanoma cells. We have shown that PUMA and BIM are the main mediators of PLX4032-induced apoptosis in BRAF V600E melanoma cells. Further insight into the key regulators of cell death in melanomas may facilitate the development of combination therapies to enhance the efficacy of PLX4032. Potential therapeutic targets of particular interest are the endogenous antagonists of PUMA and BIM, the BCL-2-like pro-survival proteins. BCL-2, and its homologues, BCL-XL, MCL-1 and BFL-1, have all been reported to contribute to different stages of melanoma development. [25] [26] [27] Western blot analysis identified BCL-2, BCL-XL and MCL-1 at readily detectable levels in the BRAF V600E melanoma cell lines tested and their expression levels did not significantly change when these cells were treated with PLX4032, except for the Malme3M cells, in which a minor decrease of all pro-survival BCL-2 proteins was observed (Figure 4a ). BFL-1 protein levels could not be determined, as there are no reliable antibodies available.
We next investigated, which of the pro-survival BCL-2 protein/s is/are critical for the sustained survival and growth of mutant BRAF-driven melanoma cells, both under normal conditions and following PLX4032 treatment. Previous studies have demonstrated that PLX4032-induced killing of melanoma cells can be augmented by co-treatment with ABT-737, a BH3 mimetic that inhibits BCL-2, BCL-XL and BCL-W. 7, 11, 14 We sought to extend these findings by determining which of these three pro-survival BCL-2 family member(s) targeted by ABT-737 is/are critical for melanoma cell survival. The BRAF mutant melanoma lines were treated with the BCL-2 selective inhibitor, ABT-199, 28 or the BCL-XL-specific compound, A-1155463, 29 either alone or in combination with PLX4032. As a control, the cells were also treated with ABT-737 or ABT-737 plus PLX4032. As reported, 7, 14 pronounced induction of apoptosis was seen in BRAF mutant melanoma cell lines when they were exposed to a combination of PLX4032 plus ABT-737 (Figure 4b ). Inhibition of BCL-XL in combination with PLX4032 led to a similar extent of apoptosis in the BRAF mutant melanoma cells, whereas the combination of BCL-2 inhibition with PLX4032 had much lower impact. Notably, neither ABT-737, ABT-199 nor A-1155463 induced significant cell death as single agents in any of the melanoma cell lines tested (Figure 4b) . To examine the role of BCL-XL in the survival of the low passage patient-derived melanoma lines, cells were treated with a combination of PLX4032 plus the BCL-XL inhibitor, A-1155463. These compounds potently cooperated in the killing of the LM-MEL-33 cells, but only showed additive effects in the LM-MEL-28 cells (Supplementary Figure 3) . The latter finding can probably be attributed to the fact that treatment with PLX4032 alone potently kills LM-MEL-28 cells, hence no further increase in killing would be expected in this line. Our results show that BRAF V600E melanoma cells rely on BCL-XL but not on BCL-2 or BCL-W for their survival, particularly when treated with PLX4032. In addition, our data reveal that inhibition of BCL-XL by A-1155463 only sensitizes BRAF mutant melanoma cells to apoptosis, and that PLX4032-mediated upregulation of PUMA and BIM is critical for their efficient killing.
HGF-induced resistance of BRAF V600E melanoma cell lines to PLX4032 is mediated by inhibiting upregulation of PUMA and BIM. Despite a strong initial response of BRAF V600E melanoma cells to PLX4032, often resulting in profound tumour regression, relapse of drug-resistant tumours invariably occurs. 15 Recent studies have implicated HGF/cMET signalling as an important resistance mechanism acquired by BRAF mutant melanoma cells following PLX4032 treatment. 16, 17 HGF mediates its activity through activation of the cMET receptor tyrosine kinase that is expressed on the surface of human melanoma cell subsets. 30 We quantified cMET expression on the BRAF V600E melanoma cells by flow cytometry, classifying them as cMET+ or cMET-(Supplementary Figure 4a ). As expected, only the cMET+ melanoma cell lines (Malme3M, SKMEL5 and UACC62) became resistant to PLX4032 treatment when co-treated with HGF, whereas the cMET-lines (M14 and UACC257) remained sensitive to this inhibitor of mutant BRAF (Figure 5a and Supplementary  Figure 4b) .
We hypothesized that modulation of BCL-2 family member levels is likely to contribute to HGF-mediated resistance to PLX4032. Therefore, we examined the effect of HGF on the expression of pro-survival and pro-apoptotic BCL-2 family members. HGF treatment in the presence or absence of PLX4032 did not alter the mRNA levels of any of the BCL-2 family members tested (Figure 5b ). As expected, at the protein level, HGF had no effect on any of the BCL-2 family members tested in the cMET-cell lines M14 and UACC257 (Figure 5c ). Perhaps surprisingly, addition of HGF to PLX4032-treated cMET+ cell lines (Malme3M, SKMEL5 or UACC62) did not elicit changes in the pro-survival proteins, BCL-2, BCL-XL and MCL-1. Instead, we found that HGF-mediated resistance to PLX4032-induced apoptosis by preventing the upregulation of PUMA and BIM (Figure 5c and Supplementary Figure 4c) .
HGF-induced resistance to PLX4032 can partially be overcome through BCL-XL inhibition. As BCL-XL inhibition with A-1155463 synergized with PLX4032, we investigated whether this combination could overcome HGF-mediated resistance of BRAF V600E melanoma cells to PLX4032. The cMET+ BRAF mutant cells were treated with PLX4032 in the presence of HGF and A-1155463, or as a control with ABT-737 or ABT-199. Co-treatment with A-1155463 (or ABT-737) was able to partially overcome the resistance to PLX4032 conferred by HGF in the Malme3M cells but not in the SKMEL5 cells (Figure 6a ). Co-treatment with ABT-199 had no effect. Collectively, these findings suggest that while combination therapy of PLX4032 and A-1155463 can be effective in melanoma, the presence of high levels of HGF, and potentially ligands for other receptor tyrosine kinases or other resistance mechanisms, such as those present in the SKMEL5 cells, will require inclusion of additional drugs to achieve effective combination treatment strategies.
Discussion
The high incidence of melanomas harbouring activating mutations in the BRAF kinase demonstrates the essential role for MAPK pathway signalling in the development and progression of melanoma. In this study, we investigated the underlying molecular mechanisms of the sensitivity, as well as HGF-mediated resistance to PLX4032-induced apoptosis observed in BRAF V600E melanoma cell lines. In contrast to previous studies, which solely described a role for BIM in PLX4032-induced apoptosis, 7, 14 our results show that inhibition of MAPK signalling in human BRAF V600E melanoma cell lines strongly increased expression of PUMA in addition to BIM. Pertinently, we generated BIM and PUMA single and double knockout cells and showed that PUMA was more important than BIM for PLX4032-induced killing of BRAF mutant lines. PUMA was originally identified as a direct target of the transcription factor p53 (refs 18,19) that is activated in response to many stressors, particularly DNA damage and hypoxia, and is critical for their ability to induce apoptosis. 31, 32 However, PUMA can also be upregulated and induce apoptosis in response to p53-independent apoptotic stimuli, such as cytokine withdrawal or treatment with glucocorticoids. [31] [32] [33] We generated TP53-deficient BRAF V600E melanoma cells and showed that induction of PUMA by PLX4032 is independent on TP53 activation. These results are highly significant as they show that tumours that harbour mutations in p53, or have other defects in the p53 pathway, should still be able to upregulate PUMA and respond to PLX4032 treatment.
The question remains how PUMA is upregulated in BRAF V600E melanoma cells in response to PLX4032 and how its upregulation is prevented by HGF/cMET signalling. We found that PUMA is mainly induced at the protein rather than at the mRNA level. This suggests that posttranslational modifications in PUMA may have an important role in PLX4032-induced apoptosis. Along this line, it has been shown that PUMA phosphorylation primes this protein for proteasomal degradation. 34 Future experiments are needed to investigate which component(s) of the PI3K or MAPK signalling pathways, driven by mutant BRAF and/or HGF/cMET signalling, cause PUMA phosphorylation and degradation.
Controversy surrounds the dependency of melanoma cells on different pro-survival BCL-2 family members for their sustained survival and growth. Although some report that BCL-2 is important for cell survival during the progression to malignant melanoma, 25 others reported that its expression is decreased in advanced melanomas compared with benign nevi. 26 In accordance with the latter reports, we found that treatment with the BCL-2-specific inhibitor, ABT-199, did not increase PLX4032-induced apoptosis in any of the BRAF mutant cell lines, although they had detectable BCL-2 protein levels. BCL-XL was also reported to be highly expressed in metastatic melanoma. 25 We found that inhibition of BCL-XL by the highly specific BH3 mimetic, A-1155463, did not promote apoptosis of BRAF mutant melanoma cells on its own, but greatly augmented apoptosis when combined with PLX4032. Hence, our study is the first to demonstrate that the synergistic pro-apoptotic response exerted by the combination of PLX4032 in combination with ABT-737, 7, 14 does not depend on inhibition of BCL-2 but on neutralization of BCL-XL. The finding that inhibition of BCL-XL on its own is not sufficient to induce apoptosis is probably due to the fact that the low basal levels of pro-apoptotic BH3-only proteins present in the melanoma cells are not sufficient to cause BAX/BAK activation, either directly or indirectly by blocking pro-survival MCL-1, which is also present at readily detectable levels in these cells. Therefore, PLX4032-induced upregulation of BIM and PUMA is required to reach a threshold of BH3-only proteins sufficient to block all pro-survival BCL-2-like proteins and induce apoptosis. Indeed, when BIM was overexpressed in the BRAF mutant patient cell line that was less sensitive to PLX4032 (LM-MEL-33), very potent killing was observed Figure 6 The combination of PLX4032 and BCL-XL inhibition can partially overcome HGF-mediated resistance of cMET+ BRAF mutant melanoma cells. (a) Malme3M and SKMEL5 cells were treated with DMSO (vehicle), PLX4032 (3 μM) alone or in combination with ABT-737 (1 μM) (blue bars), ABT-199 (1 μM) (green bars), A-1155463 (1 μM) (red bars), with or without addition of HGF (50 ng/ml) for 5 days and cell survival was assessed by flow cytometry. Living cells were identified as those negative for Annexin V and PI. The data are derived from three independent experimental replicates, each comprising the average of three technical replicates. The data were analyzed using Student's t-test and are presented as mean ± S.E.M.; *Po0.05, **Po0.01. (b) Under steady-state conditions, low levels of pro-apoptotic BH3-only proteins are present in the BRAF mutant melanoma cells. Hence, pro-survival proteins are able to neutralize BAX and BAK to cause survival of the cell. In the presence of PLX4032, PUMA and BIM are getting induced, which leads to sequestration of pro-survival proteins, allowing BAX and BAK to induce apoptosis. In the presence of HGF, PLX4032 mediated upregulation of PUMA and BIM is substantially diminished, and this is the underlying molecular mechanism that causes melanoma cells to develop resistance to PLX4032-induced killing. When combining PLX4032 and the BCL-XL-specific inhibitor, A-1155463, HGF-mediated resistance can partially be overcome PLX4032-induced apoptosis of melanoma cells L Rohrbeck et al ( Figure 3b ) compared with the levels of cell death seen following PLX4302 treatment. Although no clinical trials have yet been conducted with a BCL-XL selective inhibitor, our results provide evidence that certain melanomas are highly dependent on this pro-survival protein and that the combination of PLX4032 and BCL-XL inhibition could represent an attractive strategy for treatment of such cancers. Several studies have demonstrated that activation of receptor tyrosine kinases by their corresponding growth factors can render PLX4032-sensitive melanoma cells resistant to apoptosis. 16, 17 In accordance with these studies, we found that HGF could rescue cMET+ BRAF mutant melanoma cell lines from PLX4032-induced killing, whereas those melanoma lines lacking cMET did not acquire resistance. Importantly, we were able to demonstrate that resistance to PLX4032 caused by HGF was associated with a reduction in PUMA and BIM protein levels rather than an increase in the levels of pro-survival BCL-2-like proteins.
Resistance of melanoma cells to PLX4032 has been proposed to be associated with selection for HGF-expressing tumour cells, 17 and inhibition of cMET was therefore proposed as a strategy to promote killing of melanoma cells with high cMET levels. 35, 36 The small molecule drug SU11274 potently inhibits cMET tyrosine kinase activity, and this was shown to significantly reduce melanoma burden in a murine xenotransplantation model. 37 Importantly, acquired resistance to SU11274 was observed and this was associated with upregulation of PI3K/AKT and WNT pathway signalling. Therefore, combination therapies with cMET, PI3K and WNT pathway inhibitors have been proposed as a novel strategy to treat such treatment refractory melanomas. 37 In conclusion, we believe that in order to develop effective treatment strategies for melanoma patients, common mediators of resistance to PLX4032 need to be identified and targeted with suitable drugs. Signalling through PI3K/AKT and MAPK pathways by either growth factor-mediated activation of receptor tyrosine kinases or constitutively active mutants of RAS or BRAF all appear to affect the levels and activity of PUMA and BIM. If the downregulation of these two proapoptotic proteins is the most common mechanism for acquired drug resistance, then targeted therapies that keep PUMA and BIM levels high in cancer cells, or replacing their action by suitable BH3 mimetics that inhibit relevant prosurvival BCL-2 family members (BCL-XL and possibly also MCL-1 and BFL-1) may be of substantial benefit (Figure 6b ). Cell culture and generation of knockout cell lines using CRISPR/ Cas9. Cell lines were cultured in HT-RPMI 1640 culture medium supplemented with 5% foetal bovine serum (both from Thermo Fisher Scientific, Waltham, MA, USA). For lentiviral particle production, 293T cells were transiently transfected with the packaging constructs pMDL (5 μg), RSV-REV (2.5 μg) and VSVg (3 μg) along with 10 μg vector DNA encoding Cas9 or individual sgRNAs. Cells were transfected using the calcium phosphate precipitation method as described previously. 38 The generation of the Cas9 expression vector and sgRNA constructs was described recently. 20 The sgRNA sequences are as follows: -human BIM exon 2: 5′-GCCTCCCCAGCTCAGACCTG-3′ -human BIM exon 3: 5′-GCCCAAGAGTTGCGGCGTAT-3′ -human PUMA exon 2: 5′-AGCTCCCCGGAGCCCGTAGA-3′ -human PUMA exon 3: 5′-GCCGCTCGTACTGTGCGTTG-3′ -murine Bim exon 3: 5′-GCACAGGAGCTGCGGCGGAT-3′ -human TP53 exon 4: 5′-GGCAGCTACGGTTTCCGTCT-3′ -human TP53 exon 5: 5′-GAGCGCTGCTCAGATAGCGA-3′. To generate control or single knockout cell lines, Cas9-expressing cells (1 × 10 4 cells per well/six-well plate) were transduced with 500 μl lentivirus encoding human BIM or PUMA targeting sgRNAs or a murine Bim targeting sgRNA, as a negative control, in combination with 500 μl lentivirus encoding the empty sgRNA vector backbone. To generate double knockout cell lines, 500 μl human BIM sgRNA virus and 500 μl human PUMA sgRNA virus were mixed and added together to target cells. Cells were cultured in the presence of virus for 3 days before culture medium was replaced. Flow cytometry was used to determine the percentage of mCherry (Cas9) and GFP (sgRNA) double-positive cells. When the transduction efficiency was lower than 95%, then the double-positive cells were sorted as a whole population. To induce expression of the sgRNA, doxycycline-hyclate (Sigma-Aldrich) was added to the culture medium at a final concentration of 1 μg/ml. Successful target gene disruption was verified by DNA sequence analysis as described previously. For qRT-PCR analysis, cells were resuspended in TRIzol reagent (Life Technologies, Carlsbad, CA, USA) and RNA was isolated following the manufacturer's protocol. RNA was reverse transcribed into cDNA utilizing the Super Script III First Strand cDNA Synthesis Kit (Thermo Fisher Scientific). The qPCR amplification was performed on an ABI 7900 machine (Applied Biosystems, Foster City, CA, USA) under standard running conditions. Each reaction was run in triplicate and data were analyzed using the 2ΔΔCt method where Gapdh was assigned as the housekeeping gene. All qRT-PCR primers were purchased from Life Technologies. The primers with the best coverage were chosen.
Statistical analysis. Experiments were analyzed using GraphPad PRISM version 6.0d (La Jolla, CA, USA) and Excel (Microsoft 2011). Statistical differences between sample groups were calculated using unpaired two-tailed Student's t-test. P-values of o0.05 were considered statistically significant.
